title: Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9.
abstract: Paclitaxel has been widely used in the treatment of breast cancer. However, the development of drug resistance often increases the failure of chemotherapy. Growing evidence has reported the significant role of microRNAs (miRs) in drug resistance. The present study identified that miR-24 was significantly downregulated in paclitaxel-resistant (PR) breast cancer patients and in MCF-7/PR human breast carcinoma cells, and that overexpression of miR-24 could increase the effect of paclitaxel on drug-resistant breast carcinoma cells. Furthermore, miR-24 could directly bind to the 3'-untranslated region of ATP binding cassette B9 to downregulate its expression, thereby reducing drug transportation and improving the anti-tumor effect of paclitaxel on breast cancer cells. In vivo experiments also demonstrated that overexpression of miR-24 could increase the sensitivity of drug-resistant MCF-7 cells to paclitaxel. In conclusion, the present results suggested a novel function for miR-24 in reducing paclitaxel resistance in breast cancer, which may be of important clinical significance.
authors.affiliation: Department of General Surgery and Breast Cancer Center, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, P.R. China.
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Gong
authors.affiliation: Department of General Surgery and Breast Cancer Center, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, P.R. China.
authors.forename: Liu
authors.initials: L
authors.lastname: Yang
authors.affiliation: Liver Transplantation Center of The First Affiliated Hospital and Cancer Center, Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China.
authors.forename: Jun-Wei
authors.initials: JW
authors.lastname: Tang
authors.affiliation: School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P.R. China.
authors.forename: Peng
authors.initials: P
authors.lastname: Sun
authors.affiliation: Department of General Surgery and Breast Cancer Center, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, P.R. China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Hu
authors.affiliation: Department of General Surgery and Breast Cancer Center, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, P.R. China.
authors.forename: Jian-Wei
authors.initials: JW
authors.lastname: Qin
authors.affiliation: Department of General Surgery and Breast Cancer Center, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, P.R. China.
authors.forename: Xiao-Ming
authors.initials: XM
authors.lastname: Xu
authors.affiliation: Liver Transplantation Center of The First Affiliated Hospital and Cancer Center, Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China.
authors.forename: Bei-Cheng
authors.initials: BC
authors.lastname: Sun
authors.affiliation: Department of General Surgery and Breast Cancer Center, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, P.R. China.
authors.forename: Jin-Hai
authors.initials: JH
authors.lastname: Tang
keywords: ABCB9; breast cancer; miR-24; paclitaxel resistance